COMMUNIQUÉS West-GlobeNewswire

Terveystalo Plc: Managers' transactions - Cappelen
04/06/2018
Terveystalo Plc, Managers' transactions, 4 June 2018 at 10:20 EEST ____________________________________________ Person subject to the notification requirement Name: Cappelen, Ulf Position: Member of the Board/Deputy [...]
Terveystalo Plc: Managers' transactions - Ahdekivi
04/06/2018
Terveystalo Plc, Managers' transactions, 4 June 2018 at 10:15 EEST ____________________________________________ Person subject to the notification requirement Name: Ahdekivi, Eeva Position: Member of the Board/Deputy [...]
PsiOxus Therapeutics Appoints Melissa Epperly as Chief Financial Officer
04/06/2018
PHILADELPHIA and OXFORD, United Kingdom, June 04, 2018 (GLOBE NEWSWIRE) -- PsiOxus Therapeutics, Ltd . (PsiOxus), a leader in gene therapy for cancer, today announced the appointment of Melissa Epperly as Chief [...]
ViroGates publishes prospectus for its initial public offering in Copenhagen
04/06/2018
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This announcement does not constitute a prospectus. No one [...]
Transactions under Novozymes’ stock buyback program
04/06/2018
Please read the full announcement in the attached PDF Attachment 2018_37_Stock_Buybackprogram_EN
New phantom share-based incentive program
04/06/2018
Orphazyme A/S Company announcement No. 07/2018 Copenhagen, June 4, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the [...]
Shire plc : Rule 2.9 Announcement
04/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 4 June 2018 Shire [...]
CMR Surgical raises $100 million in a Series B financing
04/06/2018
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical raises $100 million in a Series B financing Europe’s largest medical device financing paves way to Versius ® commercialisation Cambridge, UK, 4 June [...]
ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
04/06/2018
LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances [...]
INNATE PHARMA : Data from Phase I of monalizumab and durvalumab in MSS-CRC at ASCO 2018
04/06/2018
CLINICAL DATA FROM ONGOING PHASE I DOSE ESCALATION AND EXPANSION STUDY OF MONALIZUMAB AND IMFINZI ® (DURVALUMAB) IN COLORECTAL cancer PATIENTS PRESENTED AT 2018 ASCO annual meeting Updated clinical data show preliminary [...]
INNATE PHARMA : Données de Phase I avec monalizumab et durvalumab dans le MSS-CRC présentées au congrès ASCO
04/06/2018
Données cliniques d'un essai de Phase I évaluant monalizumab et Imfinzi® (durvalumab) chez des patients atteints d'un cancer colorectal présentées au congrès annuel de l'ASCO 2018 Les données cliniques mises à jour [...]
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
04/06/2018
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and perform diagnostic [...]
FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
04/06/2018
Demonstrates Enhanced Rate of Surgical Resection with Pamrevlumab in Patients with Previously Unresectable Disease SAN FRANCISCO, June 03, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical [...]
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
04/06/2018
Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca ® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer BOULDER, Colo [...]
Shire plc : New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting
03/06/2018
New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting New data from this observational, pharmacoepidemiology safety study included more than 35,000 patients (> [...]
IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
03/06/2018
Combination Immunotherapy Continues to Show Tolerable Safety Profile and Promising Activity With Second Dosing Cohort Showing 6 of the First 8 Evaluable Participants Exhibiting Stable Disease at First CT Scan Tumor [...]
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
03/06/2018
Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months CHICAGO, June 03, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: [...]
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
03/06/2018
Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal patients with HR+/ [...]
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO
03/06/2018
Disease Control Rate of 51 Percent Achieved at 12 Weeks Represents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma CAMBRIDGE, Mass., June 03, 2018 (GLOBE [...]

Pages